Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217070 | 0.88 | KCNH2 (0.56) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6442786 | 0.88 | KCNH2 (0.59) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6441053 | 0.85 | KCNH2 (0.64) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5032199 | 0.82 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL4211396 | 0.79 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL4204035 | 0.79 | KCNH2 (0.59) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4358412 | 0.73 | KCNH2 (0.63) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL4358403 | 0.72 | KCNH2 (0.66) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6383799 | 0.72 | KCNH2 (0.49) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4217073 | 0.71 | KCNH2 (0.80) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | KCNH2 382/4885CYP1A2 4425/4885CYP3A4 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.